News
Public · Published
China's Hengrui Pharma nine-month profit rises on out-licensing gains
Hengrui Pharma's net profit attributable to shareholders rose 20.4% year on year in the first nine months, while revenue rose 5.3%. Higher out-licensing revenue, including milestone payments from GSK and BMS, drove profit growth, and generic drug sales fell 16.4%.
Published:
Updated:
What happened
Hengrui Pharma's net profit attributable to shareholders rose 20.4% year on year in the first nine months, while revenue rose 5.3%. Higher out-licensing revenue, including milestone payments from GSK and BMS, drove profit growth, and generic drug sales fell 16.4%.
Confirmed
Global impact / market context
Out-licensing brings cash without depending on hospital sales, which means profit can grow even when core drug sales slow. Slower innovative drug growth and a 16.4% generic decline show the company needs new products to win market access, that is, approval for hospital use and reimbursement.
Analyst inference
Hengrui expects full-year innovative drug revenue growth below its initial target due to market factors. Analysts keep a buy rating on the shares, but slower hospital access and competition mean future profit depends more on deal payments and new product launches than on existing sales.
Analyst inference
What to watch
- The company plans to speed up market access and expand academic promotion for new products in the fourth quarter, which means more spending on outreach to doctors and hospitals. Confirmed
- Watch whether GSK and BMS milestone payments repeat, since one-time deal cash can lift profit in one period and leave later quarters weaker. Analyst inference
- Watch fourth-quarter innovative drug sales and generic revenue, because continued hospital access delays or competition could push full-year growth further below target. Analyst inference
Evidence
- Original source link unavailable